Adamis Pharmaceuticals Stock Price - ADMP

-0.0137 (-2.16%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Adamis Pharmaceuticals Corporation ADMP NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0555 -8.04% 0.6347 0.58 0.65 0.63 0.6902 00:00:00
Bid Price Ask Price Spread Spread % News
0.6209 0.65 0.0291 4.48% 1 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,556 1,444,775 $ 0.6205349 $ 896,533 549,488 0.47 - 3.29
Last Trade Time Type Quantity Stock Price Currency
19:59:37 formt 1,500 $ 0.621 USD

Adamis Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 39.12M 61.63M $ -39.01M -1.01 - 53.05M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Adamis Pharmaceuticals News

Loading Messages....

Latest ADMP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADMP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.670.820.580.71597851,027,190-0.0353-5.27%
1 Month0.7150.820.580.7023063501,658-0.0803-11.23%
3 Months0.640.990.490.6844605813,325-0.0053-0.83%
6 Months1.081.440.470.76233591,291,016-0.4453-41.23%
1 Year3.103.290.471.00866,372-2.47-79.53%
3 Years3.506.450.472.91769,392-2.87-81.87%
5 Years6.544310.980.473.06552,171-5.91-90.3%

Adamis Pharmaceuticals Description

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.

Your Recent History
Adamis Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.